TechJournal South
Header

Archive for the ‘Pharma’ Category

Venture capital investments decline in both dollars and deals in Q3

Wednesday, October 19th, 2011

Venture capitalists invested $6.95 billion in 876 deals in the third quarter of 2011, falling in both dollars and deal volume, according to the MoneyTree Report from PricewaterhouseCoopers LLP (PwC) and the National Venture Capital Association (NVCA), based on data provided by Thomson Reuters.

The software industry saw the highest level of funding and was one of the few to see an increase in dollars invested. Early stage funding deals represented nearly half the total dollars invested, although first time financing deals fell 22 percent.

Quarterly venture capital (VC) investment activity fell 12 percent in terms of dollars and 14 percent in the number of deals compared to the second quarter of 2011 when $7.9 billion was invested in 1,015 deals. For the first three quarters of 2011, venture capitalists invested $21.2 billion into 2,725 deals, representing 20 percent more dollars and three percent more deals as the first three quarters of 2010.

Life sciences industries see marked decline in dollars and deals

The Life Sciences (biotechnology and medical device industries combined) and Clean Technology sectors saw marked decreases in both dollars and number of deals while the Software sector enjoyed its strongest quarter in almost 10 years.

“Challenges in the regulatory environment for Life Sciences companies are prompting VCs to look to other industries to put their money to work for a faster return on their investment as indicated by the notable increase in Software investments,” remarked Tracy T. Lefteroff, global managing partner of the venture capital practice at PwC US.

“Accordingly, over the past two quarters, we’ve seen a clear shift in Life Sciences investments from Seed/Early Stage companies over to more Later Stage companies. VCs are continuing to support the companies in their pipeline but appear to be curbing their investments in new Life Sciences companies.

Despite the dip in Life Sciences and in the overall investment total for Q3, 2011 is still on track to exceed the $23.3 billion invested in all of 2010.” “Given the tremendous impact that venture capital has on company creation, it is easy to forget that our industry is small and highly susceptible to the many market forces presently at work,” said Mark Heesen, president of the NVCA.

“Public policy challenges in the life sciences and clean technology sectors are impacting investment levels this quarter as is the IPO market that basically came to a screeching halt in August.

Venture fundraising levels are the lowest they have been in nearly a decade so it is reasonable to expect investment levels to decline in the coming years. Yet despite the challenges, the industry continues to fund new companies because history has shown us that innovation always prevails and there remains significant promise across all industry sectors for these emerging growth companies.”

Software industry received highest level of funding

The Software industry received the highest level of funding for all industries with $2.0 billion invested during the third quarter of 2011. This level of investment represents a 23 percent increase in dollars, compared to the $1.6 billion invested in the second quarter, and the highest quarterly investment in the sector since the fourth quarter of 2001.

The Software industry also had the most deals completed in Q3 with 263 rounds, which represents a one percent decrease from the 267 rounds completed in the second quarter of 2011. The Biotechnology industry was the second largest sector for dollars invested with $1.1 billion going into 96 deals, falling 18 percent in dollars and 20 percent in deals from the prior quarter.

Medical device industry sees decline

The Medical Devices and Equipment industry also experienced a decline, dropping 18 percent in Q3 to $728 million, while the number of deals declined 21 percent to 74 deals.

Overall, investments in the Life Sciences sector (Biotechnology and Medical Devices) fell 18 percent in dollars and 21 percent in deals, dropping to the second lowest quarterly deal volume since the first quarter of 2005.

To the contrary, Healthcare Services investments surged with $152 million going into 11 deals, a 200 percent increase in dollars and 38 percent increase in deal volume over the second quarter. Investment in Internet-specific companies fell in the third quarter to $1.6 billion going into 231 deals. This level of investment represents a 33 percent decrease in dollars and a 21 percent decrease in deals from the second quarter when $2.4 billion went into 292 deals, a ten-year high.

Internet-specific is a discrete classification assigned to a company with a business model that is fundamentally dependent on the Internet, regardless of the company’s primary industry category.

The Clean Technology sector, which crosses traditional MoneyTree industries and comprises alternative energy, pollution and recycling, power supplies and conservation, saw a 13 percent decrease in dollars to $891 million in Q3 from the second quarter when $1.0 billion was invested.

The number of deals completed in the third quarter also declined nine percent to 80 deals compared with 88 deals in the second quarter Fourteen of the 17 MoneyTree sectors experienced decreases in dollars invested in the third quarter, including:

Telecommunications (49 percent decrease), Semiconductors (44 percent decrease), Consumer Products & Services (51 percent decrease), and Media & Entertainment (11 percent decrease).

Stage of Development Seed stage investments fell 56 percent in dollars and 26 percent in deals with $179 million invested into 89 deals in the third quarter. Early stage investments also fell seven percent in dollars and six percent in deals with $2.0 billion going into 341 deals.

Seed/early stage deals nearly half the total

Seed/Early stage deals accounted for 49 percent of total deal volume in Q3, compared to 48 percent in the second quarter. The average Seed deal in the third quarter was $2.0 million, down from $3.3 million in the second quarter. The average Early stage deal was $5.7 million in Q3, down from $5.8 million in the prior quarter.

Expansion stage dollars increased two percent in the third quarter, with $2.5 billion going into 260 deals. Overall, Expansion stage deals accounted for 30 percent of venture deals in the third quarter, up from 26 percent in the second quarter of 2011. The average Expansion stage deal was $9.6 million, up from $9.2 million in the prior quarter. Investments in Later stage deals decreased 20 percent in dollars and 30 percent in deals to $2.3 billion going into 186 rounds in the third quarter.

Later stage deals accounted for 21 percent of total deal volume in Q3, compared to 26 percent in Q2 when $2.9 billion went into 265 deals. The average Later stage deal in the third quarter was $12.5 million, which increased from $11.0 million in the prior quarter and represents the largest average deal size for Later stage companies since the third quarter of 2001.

First-time financings fell 22 percent

First-Time Financings First-time financing (companies receiving venture capital for the first time) dollars decreased 22 percent and the number of deals fell 18 percent with $1.2 billion going into 269 deals. First-time financings accounted for 17 percent of all dollars and 31 percent of all deals in the third quarter, compared to 20 percent of all dollars and 32 percent of all deals in the second quarter of 2011.

Companies in the Software, Media & Entertainment, and IT services sectors received the most first time rounds in the third quarter. There was a significant decline in the number and dollar level of first time rounds in the Life Sciences sector.

The average first-time deal in the third quarter was $4.5 million, down slightly from $4.7 million in the prior quarter. Seed/Early stage companies received the bulk of first-time investments, garnering 74 percent of the deals. MoneyTree Report results are available online at www.pwcmoneytree.com and www.nvca.org

Software companies dominate Deloitte’s 2011Tech Fast 500

Wednesday, October 19th, 2011

DeloitteSoftware companies dominate on Deloitt’s 2011 Technology Fast 500, an annual ranking of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Software firms account for 39 percent of the entire list, with 194 companies. Not surprisingly the West is home to the most (37%) Fast 500 tech firms.

Five of the top 10 companies in this year’s rankings are from the software industry, including Avigilon (No. 4), ServiceNow (No. 5), NexJ Systems Inc. (No. 6), Real Matters (No. 7) and HubSpot (No. 8).

MAKO Surgical Corp., an orthopedic medical device company based in Fort Lauderdale, Fl., ranked No. 1.

MAKO Surgical Corp.’s fiscal year revenue of $44.29 million and five year fiscal growth rate of 70,211 percent topped this year’s ranking which is based on the percentage of fiscal year revenue growth from 2006 to 2010.

“Deloitte’s Technology Fast 500 recognizes some of the most exciting technology companies in North America today,” saidEric Openshaw, vice chairman and U.S. Technology, Media & Telecommunications leader, Deloitte LLP. “We are proud to honor MAKO Surgical Corp., and we congratulate all of the ranked companies for their extraordinary achievements.”

The top ten ranked companies are as follows:

2011 Rank Company Sector Revenue Growth(2006 to 2010) City, State
1 MAKO Surgical Corp.www.makosurgical.com Medical Equipment 70,211 percent Ft. Lauderdale, FL
2 Accedian Networkswww.accedian.com Communications/Networking 50,136 percent Saint-Laurent, QC
3 RTI Cryogenics Inc.www.rticryo.com Clean Technology 46,278 percent Cambridge, ON
4 Avigilonwww.avigilon.com Software 38,796 percent Vancouver, BC
5 ServiceNowwww.service-now.com Software 32,048 percent San Diego, CA
6 NexJ Systems Inc.www.nexj.com Software 29,161 percent Toronto, ON
7 Real Matterswww.realmatters.com Software 28,265 percent Markham, ON
8 HubSpotwww.hubspot.com Software 27,746 percent Cambridge, MA
9 AVI BioPharma, Inc.www.avibio.com Biotechnology/Pharmaceutical 25,483 percent Bothell, WA
10 ARIAD Pharmaceuticals, Inc.www.ariad.com Biotechnology/Pharmaceutical 19,875 percent Cambridge, MA

Mark Jensen, managing partner of Deloitte’s national venture capital services group, added, “During the 17 years Deloitte has published this list, some deeply entrenched patterns have evolved. Software companies have dominated year-over-year, and the western and northeastern regions of the U.S. have consistently attracted innovative, high growth companies.”

West region yields highest concentration of Fast 500 companies, followed by Northeast

Overall, the West remains home to the highest concentration of Technology Fast 500 companies (37 percent), trailed by the Northeast (24 percent), Canada (15 percent), Southeast (12 percent), Midwest (6 percent), and Southwest (6 percent).

Region Percent of List Fastest-growingCompany in the

Region

City, State
West 37 percent ServiceNowwww.service-now.com San Diego, CA
Northeast 24 percent HubSpotwww.hubspot.com Cambridge, MA
Canada 15 percent Accedian Networkswww.accedian.com Saint-Laurent, QC
Southeast 12 percent MAKO Surgical Corp.www.makosurgical.com Ft. Lauderdale, FL
Midwest 6 percent Gevo, Inc.www.gevo.com Englewood, CO
Southwest 6 percent SoftLayerwww.softlayer.com Dallas, TX

Software sector dominates – again

Five of the top 10 companies in this year’s rankings are from the software industry, including Avigilon (No. 4), ServiceNow (No. 5), NexJ Systems Inc. (No. 6), Real Matters (No. 7) and HubSpot (No. 8).

The software sector comprises 39 percent of the overall list with 194 companies, followed by biotechnology (15 percent), communications/networking (12 percent) and Internet (11 percent).  Medical equipment, scientific/technical instrumentation, semiconductor, computers/peripherals, media/entertainment and clean technology companies round out the remaining 23 percent of the list.

The percentage of companies from industry sectors are represented on Deloitte’s Technology Fast 500 as follows:

Sector Percent of List Fastest-growingCompany in the Sector City, State
Software 39 percent Avigilonwww.avigilon.com Vancouver, BC
Biotechnology/Pharmaceutical 15 percent AVI BioPharma, Inc.www.avibio.com Bothell, WA
Communications/Networking 12 percent Accedian Networkswww.accedian.com Saint-Laurent, QC
Internet 11 percent SAY Media, Inc.www.saymedia.com San Francisco, CA
Medical Equipment 7 percent MAKO Surgical Corp.www.makosurgical.com Ft. Lauderdale, FL
Clean Technology 5 percent RTI Cryogenics Inc.www.rticryo.com Cambridge, ON
Semiconductor 4 percent MaxLinear, Inc.www.maxlinear.com Carlsbad, CA
Media and Entertainment 3 percent Collectivewww.collective.com New York, NY
Computers/Peripherals 2 percent PlumChoicewww.plumchoice.com Billerica, MA
Scientific/TechnicalInstrumentation 2 percent Digital Ally, Inc.www.digitalallyinc.com Overland Park, KS

Technology Fast 500 Ranking Methodology

In order to be eligible for Technology Fast 500™ recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company’s operating revenues.  Companies must have base-year (2006) operating revenues of at least $50,000 USD or CD, and current-year (2010) operating revenues of at least $5 million USD or CD. Additionally, companies must be in business for a minimum of five years, and be headquartered within North America.

Ranking is rounded to the nearest percentage point. Revenue growth is calculated as follows: [(FY'2010 revenue – FY'2006 revenue)/ FY'2006 revenue] x 100.  For example, a company with reported revenues of $350,000 in 2006 and$7,500,000 in 2010 would have fiscal year revenue growth of 2,043 percent during the period from 2006 to 2010.

The ranking is compiled from nominations submitted directly to the Technology Fast 500™ Web site, and public company database research conducted by Deloitte.  Deloitte has not audited the ranking and, accordingly, does not express an opinion or any other form of assurance on it.  Some companies that may be eligible to appear on the ranking are not included because they did not submit the required information or otherwise declined to participate.

For additional detail on the Technology Fast 500™ including the complete list and qualifying criteria, visit www.fast500.com.

As used in this document, “Deloitte” means Deloitte & Touche LLP, a subsidiary of Deloitte LLP. Please seewww.deloitte.com/us/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries. Certain services may not be available to attest clients under the rules and regulations of public accounting.

 

SOURCE Deloitte

Back to topRELATED LINKS
http://www.deloitte.com

Internet Summit bringing 120 digital gurus to Raleigh Nov. 15-16

Thursday, October 6th, 2011
Interent Summit 2011TechMedia’s Internet Summit 2011 at the Raleigh, NC Convention Center Nov. 15-16  is jam-packed with top level content focused on the latest digital trends, online marketing techniques and IT best practices at the largest digital event in the Southeast.
 
The Internet Summit features two full days of learning mixed with awesome parties, great networking and entertaining keynotes.  Here’s a sampling of topics that will be addressed:

  • Online Video
  • Cloud Panel
  • Ecommerce Trends
  • Reputation Management
  • Security/Risk Management
  • Startup Strategies
  • Enterprise 3.0 Panel
  • Email Marketing
  • Mobile Analytics
  • Advanced SEO
  • Big Data
  • Measuring Social
  • Design
  • Paid Search
  • CIO/CTO Panel
  • Online Advertising
  • Location Marketing
  • Marketing Through Facebook & Twitter
  • Virtualization
  • Social Media Marketing
  • Internet Entrepreneurship Panel
  • and much more.

Hear from the founders of companies like Gowalla, TheLadders, Twitpic & HowStuffWorks!  Not enough?  How about a Keynote from Top rated SXSW keynote and ‘Social Media King’ Gary Vaynerchuk? That’s just a sampling of the over 120 speakers and presenters that will be on hand.

Early confirmed presenters include:
  • Gary Vaynerchuk, Co-Founder, VaynerMedia 
  • Josh Williams, Co-founder & CEO, Gowalla 
  • Mac Cendella, Founder & CEO, The Ladders 
  • Marshall Brain, Founder, How Stuff Works 
  • David Perry, Business Development Executive, Google
  • Liz Strauss, Co-founder, SOBcon & LizStrauss.com 
  • Noah Everett, Founder, TwitPic and Heello 
  • Jack Krawczyk, Sr Product Marketing Mgr, StumbleUpon 
  • Traug Keller, Sr VP of Production, ESPN
  • Jeff Ragovin, Chief Revenue Officer, Buddy Media 
  • Peggy Fry, Chief Revenue Officer, Clearspring Technologies
  • Mike Relm, Founder, Relmvision 
  • Bob Young, Founder & CEO, LuLu.com
  • Donna DeMarco, Co-Founder & VP, Viddler 
  • Ryan Mannion, Chief Technology Officer, Politico 
  • Fran Maier, President & Executive Chair, TRUSTe
  • Jerry Cuomo, CTO WebSphere, IBM
  • Prerna Gupta, CEO, Khush
  • Kevin Dando, Dir Digital & Education Communication, PBS
  • Clint Smith, Co-Founder & CEO, Emma
  • Matt Crenshaw, VP of Marketing, Discovery Communications
  • Scott Gunter, VP of User Experience, Usability Sciences 
  • Lindsay Wassell, Partner & Consultant, KeyphraSEOlogy 
  • Steve Ashley, VP Internet Marketing, Market America 
  • Gerard Bush, Chief Creative Dir, The brpr Group 
  • Rob Ousbey, VP Operations Seattle, Distilled 
  • David Gudai, VP of Marketing, Storkie 
  • Glenn Mersereau, Dir of Internet Marketing, PHE
  • Jim Tobin, President, Ignite Social Media
  • Kevin Pomplun, CEO, SkyGrid 
  • Sherry Bastion, Web Creative Director, Lenovo 
  • John Lovett, Sr Partner, Web Analytics Demystified
  • Drew Diskin, Dir of Interactive & Web Strategy, Penn Medicine 
  • Lynette Montgomery, VP Ecommerce, Burt’s Bees 
  • Noah Dinkin, Co-Founder & President, FanBridge 
  • Jessica Bowman, SEOinhouse.com
  • David Gudai, VP of Marketing, Storkie
  • Todd Moy, Sr User Experience Designer, Viget Labs
  • Donna Bedford, Global SEO Lead, Lenovo
  • Francis Shepherd, Media Evangelist
  • Dallas Lawrence, Chief Digital Strategist, Burson-Marsteller
  • Thuy LeDihn, Senior Marketing Manager, .ORG
  • Adam Covati, Co-founder & CTO, Argyle Social
  • Chris Condayan, American Society for Microbiology
  • Kyle Scott Richardson, Social Media, NC National Guard
  • Cara Rousseau, Social Media Manager, Duke University
  • Loren Baker, VP of Marketing, Blueglass
  • Matthew Munoz, Partner & Chief Design Officer, New Kind
  • Jill Whalen, CEO, HighRankings
Register today to secure your seat!

Social media can be an effective recruitment tool for clinical trials

Tuesday, June 28th, 2011

Blue ChipBlue Chip Patient Recruitment, a division of global, full-service marketing agency Blue Chip Marketing Worldwide, has authored a white paper advising patient recruitment specialists on how to effectively implement social media into their recruitment strategies.

The white paper, titled, “Patient Recruitment and the E-patient: A Survey Analysis,” is available at www.bluechipww.com/healthcare. It summarizes the results of a market research survey Blue Chip conducted of 179 adults from February through April 2011 and offers 11 key takeaways for recruitment specialists to consider when interacting with the E-Patient population (actively-engaged members of health-related social media networks). These include:

  • Engage a Physician: Credibility continues to be one of the biggest obstacles for E-Patients when considering participating in a clinical trial. Eighty percent of survey respondents prefer to receive clinical trial information online from a physician, indicating that physicians need to play an active role in online communities. Only 19% of respondents were comfortable receiving information through a Facebook wall and 14% comfortable receiving it via a Twitter profile.
  • Develop Approved Responses in Advance: Of even greater concern than credibility is clinical trial safety, as clinical trials in general have adopted a negative stigma within society. Forty-one percent of surveyed individuals expressed most concern with trial safety, as compared with only 36 percent who were more concerned about trial credibility. The white paper recommends developing a variety of approved responses prior to launching social campaigns, which can address an E-Patient’s concern about drug safety and other frequently asked questions.
  • Be Relevant to the Audience: While the goal is to recruit patients for the trial, it is important to first establish a role in the community. If the communication via online message forums is solely about the trial, the representatives will most likely be seen as intruders and message pushers. They can build credibility by posting relevant content, being attentive to the tenor of the dialogue, being consistent with the frequency of their interactions and being timely with responses.

“Social media has the potential to connect hundreds of thousands of interested participants to clinical trials immediately,” said Stanton Kawer, CEO of Blue Chip Marketing Worldwide. “This white paper sheds new light on what these individuals are looking for when they consider enrolling in a clinical trial, and illustrates how Blue Chip Patient Recruitment is effectively using social media to assist our pharmaceutical clients with recruitment solutions.”

The white paper also cited a huge untapped population of potential clinical trial participants among E-Patients. Eighty-one percent of those surveyed said they were interested in participating in clinical trials, but of that group, only 16 percent have done so.

A key reason for this could be a serious lack of awareness about participation opportunities. Only 30 percent of respondents said that they were aware of such major patient recruitment sites as ClinicalTrials.gov, CenterWatch.com and CISCRP.org, suggesting there is tremendous opportunity to educate E-Patients and build awareness. More targeted social media strategies can help recruitment specialists disperse this information where it is needed most.

Improving the efficiency of clinical trials through social media communication can have huge implications for the healthcare industry. An estimated 85 percent of clinical trials experience delays in patient recruitment. According to Life Science Leader, one month of delays can account for $40 million in lost sales for a newly-approved prescription drug.

PerkinElmer buys NC-based Artus Labs

Thursday, March 24th, 2011

ArtusLabsMORRISVILLE, NC – Massachusetts-based health and safety-focused PerkinElmer (NYSE:PKI) has acquired Morrisville-based Artus Labs, which sells Web 2.0 enabled software to the phamraceutical and related industries.

PerkinElmer also purchased CambridgeSoft and says the cash purchase price for both companies was about $220 million.

Venture-backed ArtusLabs offers the Ensemble scientific knowledge platform, to accelerate research and development in the pharmaceutical, chemical, petrochemical and related industries. Its flagship product,

“Ensemble, blends social networking, collaboration, and refined scientific data mining to drive the research process, leading to faster time to market,” said David Jones, a partner with Southern Capitol Ventures.

Investors in Artus, include Southern Capitol Ventures and Hatteras Venture Partners.

Artus CEO Robin Smith will stay with PerkinElmer and keep an office in Morrisville.

SCV invested in Smith’s first company, Synthematix which sold in 2005 and then SCV and Hatteras Venture Partners seeded ArtusLabs in August 2007.

Aerie Pharmaceuticals closes $30M round for glaucoma treatment

Monday, March 7th, 2011

AerieRESEARCH TRIANGLE PARK, NC – Aerie Pharmaceuticals, Inc, a biotechnology company focused on the discovery and development of medical innovations in ophthalmology, has closed a $30 million Series B financing. Clarus Ventures and Sofinnova Ventures co-led the round, with participation from Osage University Partners, and existing investors Alta Partners and TPG Biotech.

The financing is one of the largest we’ve seen regionally so far this year. The company has raised more than $75 million since it was founded in 2005 by CEO Thomas J. Van Haarlem. Van Haarlem was previously vice president of the surgical ophthalmology business at Pfizer.

Aerie expects to use proceeds from this financing to fund continued development of Aerie’s broad product portfolio in glaucoma and advance the company’s lead product, AR-12286, a first-in-class selective Rho-kinase inhibitor, into Phase 3 trials by the end of 2011.

When you go for you eye examine and the doctor puffs air at your eye, he’s testing for glaucoma symptoms. As baby boomers in the population age, more incidents of glaucoma are likely.

“Despite the fact that glaucoma is a progressive disease, there has not been a drug with a new mechanism of action approved in the glaucoma field since the mid-nineties,” said Dr. Anand Mehra of Sofinnova. “Patients often need several drugs to control their disease, and physicians have limited options with these older mechanisms. We believe that AR-12286′s new MOA, strong efficacy, excellent tolerability, and once daily dosing can provide real value to patients at risk of losing their vision.”

AR-12286 is designed to lower intraocular pressure. Aerie reported positive top-line data from a Phase 2b trial with AR-12286 last September. Additional Phase 2 studies are planned for 2011 to further elucidate the unique clinical benefits of AR-12286.

In conjunction with the financing, Dennis Henner, PhD, Managing Director at Clarus Ventures, joined Aerie’s Board of Directors. Mehra, MD, a partner at Sofinnova Ventures joined the board in September of 2010.

The company is also pursuing several other pipeline programs also aimed at glaucoma therapy.

“The more we learn about the unique, clinical benefits of AR-12286, the more enthusiastic we are about its prospects as an important and differentiated glaucoma treatment, both as monotherapy and in combination with existing glaucoma drugs,” said Dr. Henner.

TechJournal South is a TechMedia company. TechMedia presents the annual conferences:

SoutheastVentureConference: www.seventure.org

Internet Summit: www.internetsummit.com

Digital East: www.digitaleast.com

Digital Summit: www.digitalsummit.com

Viamet Pharma closes $25M equity round for drug improvement tech

Tuesday, February 22nd, 2011

ViametMORRISVILLE, NC- Viamet Pharmaceuticals Inc. has raised $25 million in equity financing, according to a regulatory filing. The company focuses on enzymes  that contain a metal, typically zinc or iron. About ten percent of current drugs target these “metalloenzymes.” Viamet’s technology makes those drugs more effective and safer, the company has said.

The company, founded in 2005, raised a $4 million round in 2007 and an $18 million B round in 2009 from Novartis Option Fund and Lilly Ventures. Existing investors who participated included Durham-based Intersouth Partners and Hatteras Venture Partners, also of Durham.

The filing with the US Securities and Exchange Commission disclosing the current raise lists Intersouth, Haatteras, and Novartis Option Fund in Cambridge, Mass.; Lurie Investment Fund in Chicago; and Indianapolis’ Lilly Ventures, a venture capital subsidiary of Eli Lilly and Co.

Other investors in the company include Headlands Ventures and Astellas Venture Management.

According to the company’s website, Viamet develops traditional small molecule compounds that exploit validated metalloenzyme targets in the fields of infectious disease and oncology.  All of Viamet’s therapeutic programs target indications with blockbuster potential and where current therapies have significant clinical deficiencies that can be addressed by the company’s technology.

TechJournal South is a TechMedia company. TechMedia presents the annual conferences:

SoutheastVentureConference: www.seventure.org

Internet Summit: www.internetsummit.com

Digital East: www.digitaleast.com

Digital Summit: www.digitalsummit.com

Boca Raton-based Managed Maintenance names Tina Lux-Boim CEO

Tuesday, February 15th, 2011

MMIBOCA RATON, FL - Managed Maintenance Inc., which sells a suite of complete contract management process optimization solutions, has promoted Tina Lux-Boim CEO.

Lux-Boim served as president of the company since its founding in 2007. Lux-Boim brings nearly 20 years of experience in the technology industry, with in-depth expertise in hardware service and maintenance and software licensing.

She was recently named one of CRN’s “2010 Women of the Channel”, which celebrates the accomplishments of those female executives making their mark in the IT channel.  Lux-Boim is a noted featured speaker at both maintenance and support conferences and SaaS provider events.

MMI says its solutions enable technology manufacturers (OEMs), their channel partners, distributors and service providers to maximize service contract and equipment replacement revenues, and help end user organizations ensure uninterrupted maintenance and support coverage.

Durham-based Chimerix closes $45M round for antivirals

Monday, February 14th, 2011

ChimerixDURHAM, NC – Chimerix, a company developing orally available broad spectrum antiviral therapeutics, has close a $45 million sixth round of financing.  New Leaf Venture Partners, Pappas Ventures and Morningside Group, as well as existing investors Canaan Partners, Sanderling Ventures, Alta Partners, Asset Management Company and Frazier Healthcare Ventures all participated in the funding.

The need for effective broad spectrum antiviral treatments is pressing.

The company’s lead candidate, CMX001, is in Phase 2 clinical trials for potentially fatal CMV infection in transplant and immunocompromised patients, and is being developed as a potential broad spectrum antiviral agent for the treatment of life-threatening double-stranded DNA viral diseases.

Chimerix recently commenced an open-label clinical study to provide CMX001 to critically-ill patients with life-threatening disease caused by any of 12 different dsDNA viral infections, (such as adenovirus, herpes viruses (cytomegalovirus, herpes simplex virus and Epstein Barr virus), polyoma viruses (BK virus and JC virus), and poxviruses).

Chimerix’s second clinical-stage antiviral compound, CMX157, a potent nucleoside analogue with activity against HIV and hepatitis B, has the potential to directly address several limitations of current HIV therapies.  Chimerix is developing CMX157 for the treatment of HIV infection including those caused by multi-drug resistant viruses.

Both CMX001 and CMX157 combine Chimerix’s proprietary PIM conjugate technology with high-value antiviral compounds, transforming the way compounds are absorbed, distributed, metabolized and excreted to create new chemical entities with potent antiviral action and reduced toxicities.

Computable Genomix lands investment for biomarker tests

Wednesday, January 26th, 2011

Computable GenomixMEMPHIS, TN – Memphis-based Computable Genomix has secured an investment in an undisclosed amount Memphis-based venture capital firm Innova to pilot a novel process for developing genetic biomarker tests.

Biomarkers are used to predict how a person will respond to drug therapy or to determine their risk of contracting a disease.

Leveraging its next-generation computational discovery capability (patent-pending), Computable Genomix is developing highly targeted genetic biomarker tests for clinical researchers.

These tests will help address pressing pharmacogenomic and other clinical questions and enhance the ability of physicians to bring personalized medicine to their patients.

“Current approaches to genetic biomarker development require clinical researchers to work with thousands of patient samples and sift through millions of possibilities to pinpoint a handful of potential biomarkers for further evaluation,” said Brad Silver, CEO of Computable Genomix.

“Using Computable’s very targeted tests, clinical researchers need fewer patient samples to assess a small number of high-value biomarkers. The end result is savings of time and money.”

“As an incubator company at the Memphis Bioworks Foundation, we have closely followed the evolution of Computable Genomix from a supplier of software to a developer of proprietary biomarker tests,” said Innova partner Jan Bouten. “We are very excited about Computable’s opportunity in the burgeoning biomarker market and its prospects for accelerating their use in clinical practice.”